ARDX - Ardelyx Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Company Name, Ticker, Customers, else..

Ardelyx inc (NASDAQ: ARDX)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Price: $3.7800 $0.07

1.887%

Day's High:	$3.7799999713897705	Week Perf:	0.00
Day's Low:	$ 3.68	30 Day Perf:	-22.38 %
Volume (M):	2,973,292	52 Wk High:	$ 8.40
Volume (M$):	$ 0	52 Wk Avg:	$5.81
Open:	$3.68	52 Wk Low:	$3.68

ARDX Charts & Quotes

ARDX Charts & Quotes

Ardelyx Inc Company Profile

Company's Segments

Market Capitalization (Millions $)	929
Shares Outstanding (Millions)	246
Employees	489
Revenues (TTM) (Millions $)	428
Net Income (TTM) (Millions $)	-58
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	1

Business Description

Ardelyx Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for gastrointestinal and cardio-renal diseases. They are committed to providing improved options for patients suffering from chronic and debilitating conditions. Ardelyx's research and development efforts are centered around developing novel oral therapeutics targeting specific biological mechanisms within the gut to address unmet medical needs. Their aim is to develop effective and safe treatments that improve patient outcomes and quality of life.

Company Address: 400 Fifth Avenue Waltham 2451 MA
Company Phone Number: 675-2739 Stock Exchange / Ticker: NASDAQ ARDX

Reports on Competition

Suppliers At a Glance

Stock Performances by Major Competitors

5 Days	Decrease / Increase

CPRX		0.06%
IRWD		3.15%
ISCO	-19.16%
LFCR	-3.08%
RCUS		1.54%
SBFM	-0.87%
• View Complete Report

Ardelyx inc News

Clinical Study

Ardelyx to Present Promising OPTIMIZE Study Findings of XPHOZAH (Tenapanor) at National Kidney Foundation Spring Cl...

Published Tue, Apr 1 2025 5:18 AM UTC

WALTHAM, Mass. March 31, 2025 Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative first-in-class medicines, has exciting news to share with the medical community. An abstract highlighting a post-hoc analysis of the OPTIMIZE Study, which represents a substantial advancement in the...

Product Service News

Ardelyx Inc Navigating Challenges and Seizing Opportunities in the Pharmaceutical Sector

Published Mon, Jan 13 2025 1:06 PM UTC

Ardelyx Inc has recently provided an update that illuminates its evolving commercial landscape and strategic priorities, aimed at enhancing its position within the pharmaceutical industry. Following a notable ascent in commercial momentum throughout 2024, the company recorded net product sales revenue of approximately $319 million in the United States, an impressive mileston...

Clinical Study

Advancements in Chronic Kidney Disease Management Ardelyx Presents New Data on Tenapanor at ASN Kidney Week

Published Tue, Oct 15 2024 12:00 PM UTC

: Ardelyx, Inc. a biopharmaceutical company recognized for its innovative approaches in addressing critical unmet medical needs, recently announced their plan to present additional data on XPHOZAH (tenapanor) at the American Society of Nephrology s Kidney Week. This article provides an overview of the upcoming presentation and the significance of tenapanor as a versatile t...

Management Announcement

Navigating the Complex Terrain of IBS-C: Ardelyxs Journey Amidst Financial Challenges and Patient Needs

Published Wed, Oct 9 2024 12:05 PM UTC

In an era where healthcare innovation is paramount, Ardelyx, Inc. a biopharmaceutical entity based in Waltham, Massachusetts, has recently made strides in addressing a critical gastrointestinal disorder—irritable bowel syndrome with constipation (IBS-C)—through the publication of a comprehensive review article. This piece, featured in Clinical and Experimental Gastroent...

Announcement

Rosen Law Firm Urges Ardelyx, Inc. Investors to Act Before October 15 Deadline in Securities Class Action

Published Tue, Oct 1 2024 5:18 PM UTC

In a timely announcement, the Rosen Law Firm, recognized as a leading global counsel specializing in investor rights, has urged investors of Ardelyx, Inc. (NASDAQ: ARDX) to take swift and decisive action ahead of the imminent October 15, 2024, deadline for lead plaintiffs in a significant securities class action. This alert is primarily directed towards individuals who acqui...

Fundamental Analysis

Valuation	Current
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	2.17
Price to Sales (Expected)	-
Price to Book	6.25
PEG (TTM)	-

Financial Strength	Current
Quick Ratio	2.17
Working Capital Ratio	3.49
Leverage Ratio (MRQ)	2.39
Total Debt to Equity	1.37
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

Per Share	Current
Earnings (TTM)	-0.23 $
Revenues (TTM)	1.74 $
Cash Flow (TTM)	0 $
Cash	0.97 $
Book Value	0.6 $
Dividend (TTM)	0 $

Efficiency	Current
Revenue per Employee (TTM)	874,599
Net Income per Employee (TTM)	-118,732
Receivable Turnover Ratio (TTM)	5.82
Inventory Turnover Ratio (TTM)	1.46
Asset Turnover Ratio (TTM)	0.88

Profitability Ratios	Current
Gross Margin (MRQ)	94.91 %
Operating Margin (MRQ)	-34.71 %
Net Margin (MRQ)	-39.81 %
Net Cash Flow Margin (MRQ)	-38.94 %
Effective Tax Rate (TTM)	-

Management Effectiveness	Current
Return On Assets (TTM)	-
Return On Investment (TTM)	-
Return On Equity (TTM)	-
Dividend Yield	-
Pay out Ratio (TTM)	-

Valuation
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	2.17
Price to Sales (Expected)	-
Price to Book	6.25
PEG (TTM)	-

Per Share
Earnings (TTM)	-0.23 $
Revenues (TTM)	1.74 $
Cash Flow (TTM)	0 $
Cash	0.97 $
Book Value	0.6 $
Dividend (TTM)	0 $

Financial Strength
Quick Ratio	2.17
Working Capital Ratio	3.49
Leverage Ratio (MRQ)	2.39
Total Debt to Equity	1.37
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

Efficiency
Revenue per Employee (TTM)	874,599
Net Income per Employee (TTM)	-118,732
Receivable Turnover Ratio (TTM)	5.82
Inventory Turnover Ratio (TTM)	1.46
Asset Turnover Ratio (TTM)	0.88

Profitability Ratio
Gross Margin (MRQ)	94.91 %
Operating Margin (MRQ)	-34.71 %
Net Margin (MRQ)	-39.81 %
Net Cash Flow Margin (MRQ)	-38.94 %
Effective Tax Rate (TTM)	-

Management Effectiveness
Return On Assets (TTM)	-11.91 %
Return On Investment (TTM)	-14.55 %
Return On Equity (TTM)	-38.11 %
Dividend Yield	-
Pay out Ratio (TTM)	-

Ardelyx Inc's Segments


Product sales net	98.84 %	of total Revenue
IBSRELA	74.17 %	of total Revenue
XPHOZAH	24.66 %	of total Revenue
Product supply revenue	0.37 %	of total Revenue
Licensing revenue	0.05 %	of total Revenue
Non-cash royalty revenue related to the sale of future royalties	0.74 %	of total Revenue
Licensing revenue Knight Knight	0.03 %	of total Revenue
Licensing revenue Fosun Pharma Fosun Pharma	0.02 %	of total Revenue
Product supply revenue Fosun Pharma Fosun Pharma	0.37 %	of total Revenue
Product supply revenue Kyowa Kirin Kyowa Kirin	0 %	of total Revenue
Non-cash royalty revenue related to the sale of future royalties Kyowa Kirin Kyowa Kirin	0.74 %	of total Revenue
Fosun Pharma Fosun Pharma	2.53 %	of total Revenue

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.